Business news and discussion on TalkFuse.
As Sanofi’s Pompe drug shortage drags on, some patients struggle to access treatments
Sanofi’s manufacturing problems in Ireland have disrupted supplies of its Pompe disease treatments, leaving some patients facing delayed or uncertain access. The shortage matters because Pompe is progressive, and patients and advocates say missed infusions can quickly affect health; they have also criticised Sanofi for not giving earlier warning.
The FDA inspected the plant in January 2026 and found violations involving two other drugs. Sanofi began responding in February, but the agency warned in June that it had not addressed an underlying failure to meet manufacturing requirements, and the company says resolving those concerns has contributed to the disruption. One 10-year-old patient has so far kept his fortnightly Lumizyme infusions, while an adult patient’s treatment is on hold; she says previous missed doses left her severely fatigued, short of breath and in pain.
In short
- Sanofi’s Ireland plant issues have disrupted Pompe drug supplies.
- Patients worry that delayed infusions could harm their health.
- The FDA had raised manufacturing concerns months before the shortage.
Steelman: both sides, in good faith
The strongest fair case each way — we don't pick a winner.
The case for
Patients and advocates can argue that a prolonged shortage of treatment for a progressive disease creates serious, foreseeable risks, especially when missed infusions have previously caused debilitating symptoms. They may reasonably expect Sanofi to communicate supply problems early and clearly so patients and clinicians can plan, and to treat continuity of care as an urgent priority.
The case against
Sanofi can argue that it must address manufacturing failures and comply with regulatory requirements to ensure medicines are safe and reliably made; continuing production before resolving those concerns could put patients at risk. The company says the corrective work has contributed to the disruption, and resolving complex plant issues may take time even when the consequences for patients are pressing.
Explained simply
Pompe disease is a rare inherited condition in which the body cannot properly break down a substance called glycogen. It can cause progressive muscle weakness and breathing problems. Treatment includes regular infusions of medicines such as Sanofi’s Lumizyme.
Sanofi makes its Pompe medicines at a plant in Ireland. After a US Food and Drug Administration inspection found manufacturing violations involving other medicines, the company began addressing the agency’s concerns; the FDA later said an underlying manufacturing problem remained unresolved. The disruption matters because patients rely on repeated infusions, and interruptions may affect their health.